KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
3'-deoxy-3'-[18F]fluorothymidine position emission tomography for target delineation in resected malignant gliomas before radiotherapy. This is an ASCO Meeting Abstract from the 2013 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results